Source: Xinmin Evening News, author: Gao Yang2024-11-22 16:22:16
Photo Caption: Asian Organ Transplantation Symposium (TSS-RRB- openedShanghaighai
Human organ transplantation is a key medical technology to save critical patients, which is of great significance to the development of national medicine and social progress. The Asian Organ Transplantation Symposium (TSS) , an international conference officially accredited by the International Transplant Society (TTS) and hosted by Zhongshan Hospitals, opened today (May 22) .
Since the start of organ donation pilot in 2010, our country has achieved remarkable results in terms of system design, social mobilization and standard procedures, and established a sound working system, both the quantity and quality of organ donation and transplantation have been improved. However, according to the China Organ Transplantation Development Report (2021) , the organ donation rate per million population in our country is 3.73, which still lags behind the international advanced level.
As the first approved comprehensive National Medical Center Construction Project Unit, Zhongshan Hospital affiliated to Fudan University is one of the few comprehensive hospitals qualified for heart, liver, kidney and pancreas transplantation in our country, in the field of organ transplantation led many technological innovations, completed the first relative kidney transplantation of children with Denys-Drash syndrome in China, the first sequential heart, liver and kidney transplantation in Asia, the first“Combined heart and liver transplantation” in Asia, the world’s first“Relative liver” and“Abandoned liver” double donor liver transplantation, the world’s first“Abandoned liver” liver transplantation combined with ALPPS, etc. .
Picture shows Professor Zhou Jian, Director of Zhongshan Hospital affiliated to Fudan University
Zhou Jian, head of Zhongshan’s Hospital, said that while our country had made significant progress in organ transplantation, it still faced a serious shortage of organs. This requires not only further improving the existing organ donation and distribution system to ensure fair, transparent and efficient operation, but also technological innovation. Through the use of advanced medical technologies and methods, such as the world’s first”Abandoned liver” liver transplantation combined with ALPSS surgery performed in Zhongshan Hospital, it can effectively expand the source of donors and improve the success rate of surgery, so as to alleviate the current tension between supply and demand.
However, in addition to the problem of organ source, transplant patients also face the hidden dangers of immunosuppression. They must continue to take immunosuppressants to prevent rejection, but this also weakens their resistance to outside pathogens, making them more susceptible to infection. Unusual”Opportunistic” pathogens can also pose a serious threat, especially in patients with weakened immune systems. Therefore, how to improve the immunity of patients after transplantation and reduce the risk of infection has become another urgent problem.
Picture shows ke Zhu Tongyu, vice president of Fudan University Shanghai Medical College and Professor of Kidney Transplantation, Zhongshan Hospital
In view of this situation, at the meeting, Ke Zhutongyu, vice president of the Fudan University Shanghai Medical College and Professor of kidney transplantation at Sun Yat-sen hospital, and his team first proposed an“Innovative diagnosis and treatment model for severe and special infections in organ transplantation.”. This model includes the development of new diagnostic systems to accurately diagnose pathogens, the use of phages to treat refractory bacterial infections after transplantation, and the development of BK virus vaccines to prevent viral infections. The aim is to improve patients’ ability to fight common infections and prevent rare but deadly Opportunistic infection. “We hope that in this way, we can not only significantly improve the quality of life of organ transplant recipients, but also further improve their long-term survival rate,” Zhu said. This study provides new ideas and methods for optimizing care after organ transplantation in the future, and marks an important step forward in improving transplant safety in our country.
It is reported that since 2018, professor Zhu Tongyu led the team to launch the first clinical trial of phage therapy in our country, and achieved a clinical improvement rate of 78.3% . During this period, the team also published the first phage therapy case report in our country, as well as the world’s first case set and case paper on phage therapy for covid-19 secondary bacterial infection. In 2022, the team initiated the establishment of the Chinese Phage Research Alliance, and issued the expert consensus and group standards for phage therapy and phage preparation quality standards.
Xinmin evening news reporter, Gao Yang.
